Balanced news tone
News Sentiment
OLMA sentiment intelligence
Olema Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-3.7% over one week, +20.6% over four weeks, trend inactive, and near fair-value range.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Olema (NASDAQ: OLMA) awards director 29,500 stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Market source
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 11:54
- Source
- MT Newswires
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 26 May 2026 11:00
- Source
- GlobeNewswire
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 May 2026 19:05
- Source
- Simply Wall St.
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 13:06
- Source
- Stocktwits
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 21:00
- Source
- GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 20:30
- Source
- GlobeNewswire
Olema: The Market Overreacted To Roche's SERD Failure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- Seeking Alpha
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 03 May 2026 07:00
- Source
- simplywall.st
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Market source
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- Market source
Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One‑Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- Market source
Olema Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Feb 2026 08:00
- Source
- Nasdaq
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2025 08:00
- Source
- Market source
Olema Pharmaceuticals Plans Public Offering of Common Stock to Support Breast Cancer Therapy Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Nov 2025 08:00
- Source
- Quiver Quantitative
Olema Pharmaceutical CEO Sean Bohen on the fight to end breast cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 07:00
- Source
- CNBC
Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 01:59
- Source
- Stock Titan
Olema Oncology Announces New Clinical Trial Collaboration
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Dec 2024 08:00
- Source
- GlobeNewswire